Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder

被引:29
作者
Delgado, PL [1 ]
Moreno, FA [1 ]
机构
[1] Univ Arizona, Coll Med, Dept Psychiat, Tucson, AZ 85274 USA
关键词
D O I
10.1192/S0007125000297869
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background There is a major role for serotonin in the mechanism of anti-obsessional drug action. Drugs that block uptake of noradrenaline are not effective in the treatment of obsessive - compulsive disorder (OCD), while drugs that potently beck serotonin reuptake are effective. While enhancement of serotonin neurotransmission is clearly involved in the treatment of OCD, the role of serotonin in the pathophysiology of OCD is less clear. Method This paper provides a brief, focused review of the literature regarding treatment of OCD, the effects of drugs with selective action at various serotonin receptors and results of neurotransmitter depletion studies in patients with OCD. Results Some patients with OCD may experience remission of OCD symptoms during intoxication with psychedelic drugs that have potent 5 - HT2A/2C agonist activity. These findings, coupled with results from serotonin depletion studies in depressed and OCD patients, suggest that enhancement of serotonin neurotransmission may underlie both antidepressant and anti-obsessional drug action, although the targeted brain areas may differ. Conclusions OCD may not involve a dysfunction of the serotonin system. Rather, it is more likely to involve a dysfunction of specific brain circuits, particularly in the iron tai cortex. Modulation of these circuits by serotonin neurons may underlie the specific action of anti-obsessional drugs.
引用
收藏
页码:21 / 25
页数:5
相关论文
共 30 条
  • [1] BARR LC, 1994, ARCH GEN PSYCHIAT, V51, P309
  • [2] BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P681
  • [3] BAXTER LR, 1991, ANN CLIN PSYCHIATRY, V3, P103
  • [4] CURRENT ADVANCES AND TRENDS IN THE TREATMENT OF DEPRESSION
    BLIER, P
    DEMONTIGNY, C
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) : 220 - 226
  • [5] BLOOM FE, 1995, PSYCHOPHARMACOLOGY 4, P1
  • [6] DELGADO PL, 1993, PSYCHOPHARMACOL BULL, V29, P389
  • [7] DELGADO PL, 1990, ARCH GEN PSYCHIAT, V47, P411
  • [8] DELGADO PL, 1991, PSYCHOPHARMACOL BULL, V27, P321
  • [9] Delgado PL, 1992, HDB AFFECTIVE DISORD, P219
  • [10] 5HT-2 RECEPTOR AND FLUVOXAMINE EFFECT IN OBSESSIVE-COMPULSIVE DISORDER
    ERZEGOVESI, S
    RONCHI, P
    SMERALDI, E
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1992, 7 (04) : 287 - 289